Anemia treatment in chronic renal insufficiency

Seminars in Nephrology

Volumn 22, Issue 6, 2002, Pages 474-478

  Fishbane, Steven ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN; HEMOGLOBIN;

ANEMIA; CHRONIC KIDNEY FAILURE; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG COST; HUMAN; HYPERTENSION; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; DRUG MONITORING; ECONOMICS;

ANEMIA; DRUG MONITORING; ERYTHROPOIETIN, RECOMBINANT; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; QUALITY OF LIFE;

EID: 0036850720     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/snep.2002.35963     Document Type: Article

References (44)

1. Obrador GT, Roberts T, St Peter WL, et al: Trends in anemia at initiation of dialysis in the United States. Kidney Int 60:1875-1884, 2001
2. Obrador GT, Ruthazer R, Arora P, et al: Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol 10:1793-1800, 1999
3. Ifudu O, Dawood M, Homel P, et al: Excess morbidity in patients starting uremia therapy without prior care by a nephrologist. Am J Kidney Dis 28:841-845, 1996
4. Eschbach JW, Detter JC, Adamson JW: Physiologic studies in normal and uremic sheep. II. Changes in erythropoiesis and oxygen transport. Kidney Int 18:732-745, 1980
5. Koury MJ, Bondurant MC: The mechanism of erythropoietin action. Am J Kidney Dis 18:20-23, 1991
6. Muta K, Krantz SB: Apoptosis of human erythroid colony-forming cells is decreased by stem cell factor and insulin-like growth factor I as well as erythropoietin. J Cell Physiol 156:264-271, 1993
7. Eschbach JW, Mladenovic J, Garcia JF, et al: The anemia of chronic renal failure in sheep. Response to erythropoietin-rich plasma in vivo. J Clin Invest 74:434-441, 1984
8. Jacobs K, Shoemaker C, Rudersdorf R, et al: Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 313:806-810, 1985
9. Eschbach JW, Egrie JC, Downing MR, et al: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78, 1987
10. Kazmi WH, Kausz AT, Khan S, et al: Anemia: An early complication of chronic renal insufficiency. Am J Kidney Dis 38:803-812, 2001
11. Fishbane S, Shapiro W, Dutka P, et al: A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 60:2406-2411, 2001
12. Lim VS, DeGowin RL, Zavala D, et al: Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 110:108-114, 1989
13. Kleinman KS, Schweitzer SU, Perdue ST, et al: The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: A double-blind, placebo-controlled trial. Am J Kidney Dis 14:486-495, 1989
14. Revicki DA, Brown RE, Feeny DH, et al: Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25:548-554, 1995
15. Wolcott DL, Marsh JT, La Rue A, et al: Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 14:478-485, 1989
16. Delano BG: Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 14:14-18, 1989
17. Brown DW, Giles WH, Croft JB: Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J 140:848-856, 2000
18. Benjamin EJ, Levy D: Why is left ventricular hypertrophy so predictive of morbidity and mortality? Am J Med Sci 317:168-175, 1999
19. Kaplinsky E: Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality. Cardiovasc Drugs Ther 8:549-556, 1994 (suppl 3)
20. Kannel WB, Cobb J: Left ventricular hypertrophy and mortality - Results from the Framingham Study. Cardiology 81:291-298, 1992
21. Rocco MV, Yan G, Gassman J, et al: Comparison of causes of death using HEMO Study and HCFA end-stage renal disease death notification classification systems. The National Institutes of Health-Funded Hemodialysis. Health Care Financing Administration. Am J Kidney Dis 39:146-153, 2002
22. Foley RN, Parfrey PS, Harnett JD, et al: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47:186-192, 1995
23. Levin A, Singer J, Thompson CR, et al: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 27:347-354, 1996
24. Levin A, Thompson CR, Ethier J, et al: Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 34:125-134, 1999
25. Luft FC: Erythropoietin and arterial hypertension. Clin Nephrol 53:S61-S64, 2000
26. Vaziri ND: Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 33:821-828, 1999
27. Nowicki M: Erythropoietin and hypertension. J Hum Hypertens 9:81-88, 1995
28. Kokot F, Wiecek A: Arterial hypertension in uraemic patients treated with erythropoietin. Nephron 71:127-132, 1995
29. Garcia DL, Anderson S, Rennke HG, et al: Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci U S A 85:6142-6146, 1988
30. Roth D, Smith RD, Schulman G, et al: Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 24:777-784, 1994
31. Lim VS, Fangman J, Flanigan MJ, et al: Effect of recombinant human erythropoietin on renal function in humans. Kidney Int 37:131-136, 1990
32. Abraham PA, Opsahl JA, Rachael KM, et al: Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients. Am J Nephrol 10:128-136, 1990
33. Frenken LA, Verberckmoes R, Michielsen P, et al: Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients. Nephrol Dial Transplant 4:782-786, 1989
34. Jungers P, Choukroun G, Oualim Z, et al: Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 16:307-312, 2001
35. Kuriyama S, Tomonari H, Yoshida H, et al: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77:176-185, 1997
36. Brahm M: Subcutaneous treatment with recombinant human erythropoietin - The influence of injection frequency and skin-fold thickness. Scand J Urol Nephrol 33:192-196, 1999
37. Egrie JC, Browne JK: Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84:3-10, 2001 (suppl 1)
38. Macdougall IC: An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16:14-21, 2001 (suppl 3)
39. Macdougall IC: Darbepoetin alfa: A viewpoint by Iain C. Macdougall. Drugs 61:2105-2106, 2001
40. Sunder-Plassmann G, Horl WH: The clinical potential of novel erythropoiesis stimulating protein. Expert Opin Biol Ther 1:733-739, 2001
41. Eschbach JW: Current concepts of anemia management in chronic renal failure: Impact of NKF-DOQI. Semin Nephrol 20:320-329, 2000
42. Allan GM, Innes G: Family practice residents' awareness of medical care costs in British Columbia. Fam Med 34:104-109, 2002
43. Kepple SR: Physicians care about drug costs but lack information. Am J Health Syst Pharm 57:2041, 2044, 2000
44. Glickman L, Bruce EA, Caro FG, et al: Physicians' knowledge of drug costs for the elderly. J Am Geriatr Soc 42:992-996, 1994